A roundup of some of the biggest pharma news from Belgium including Neuraxpharm's new Belgian affiliate, Novalis Biotech's investment in Rarity Bioscience, Catalent's plasmid DNA manufacturing site and a recent study on the country's clinical trial footprint. Neuraxpharm completes…
Become a PharmaBoardroom Member for free to access this contentJoin the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password…
Become a PharmaBoardroom Member for free to access this contentJoin the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password…
Become a PharmaBoardroom Member for free to access this contentJoin the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password…
Speaking exclusively to PharmaBoardroom, the EMA’s Head of Advanced Therapies Ana Hidalgo-Simon discusses steadily growing numbers of regulatory applications in the advanced therapy field, the vital importance of patient group insights, RWE collection and curation, hospital exemptions, manufacturing challenges, and more. [Advanced] therapies are complex, difficult, and have a huge public health impact, which means that the development and…
Belgium, with a total of EUR 5.5 billion in R&D spending in 2021, is the country with the fourth largest research expenditure in the EU and the first per inhabitant. …
Belgium, with a total of EUR 5.5 billion in R&D spending in 2021, is the country with the fourth largest research expenditure in the EU and the first per inhabitant. …
In an extensive recent PharmaBoardroom conversation, EMA Head of Advanced Therapies Ana-Hidalgo-Simon highlighted some of the most important trends around advanced therapy regulation in Europe. Hidalgo-Simon touched on why moderate…
See our Cookie Privacy Policy Here